A review of several anticancer chemicals derived from natural medicinal plant
DOI:
https://doi.org/10.61173/cs1rtq14Keywords:
cancer, natural medicinal plant, vinca alkaloids, taxol, marine algaeAbstract
Humans have used natural plants and plant-derived medicines to cure various diseases for thousands of years. Of all the diseases that humans are facing, cancer is one of the most destructive ones. Scientists have studied anticancer chemicals from natural plants for decades, and some chemicals show significant effects against cancer and are applied widely in clinical use. Vinca alkaloids are a type of chemical derived from Catharanthus roseus. Members of the vinca alkaloids have been used in many chemotherapy regimens. Taxol is one of the most famous plant-derived medicines against cancer. Scientists have focused more than twenty years on improving its synthesis route. Solanine comes from plants in the genus Solanum. This kind of plant is used in TCM for cancer treatment. Apart from these land plants, marine plants and marine photosynthetic algae are also sources of antitumor agents. Carrageenan and Fucoidan are two examples of antitumor-active compounds derived from seagrass. They have both cytotoxicity and adjuvant ability. In the future, there will be more research on the improvement of the synthetic route of existing herbal compounds, the discovery of new herbal compounds, and the better utilization and combination of herbal compounds, and finally lead to better application of natural plant medicine against cancer.
References
[1] Newman, D. J., Cragg, G. M., & Snader, K. M. (2000). The influence of natural products upon drug discovery. Natural product reports, 17(3), 215–234. https://doi.org/10.1039/ a902202c
[2] Cragg, G. M., & Newman, D. J. (2002). Drugs from nature: Past achievements, prospects. Advances in Phytomedicine, 1, 23-37. https://doi.org/10.1016/S1572-557X(02)80010-1
[3] The Papyrus Ebers: The Greatest Egyptian Medical Document. Translated by Ebbell, Bendix. Copenhagen: Levin & Munksgaard. 1937. LCCN 37020036
[4] Spill, F., Guerrero, P., Alarcon, T., Maini, P. K., & Byrne, H. M. (2015). Mesoscopic and continuum modeling of angiogenesis. Journal of Mathematical Biology, 70(3), 485. https://doi.org/10.1007/s00285-014-0771-1
[6] Basile, K. J., & Aplin, A. E. (2012). Resistance to Chemotherapy: Short-Term Drug Tolerance and Stem Cell-Like Subpopulations. Advances in Pharmacology (San Diego, Calif.), 65, 315. https://doi.org/10.1016/B978-0-12-397927-8.00010-5
[7] Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575(7782), 299-309. https:// doi.org/10.1038/s41586-019-1730-1
[8] Newman, D. J., Cragg, G. M., & Snader, K. M. (2000). The influence of natural products upon drug discovery. Natural product reports, 17(3), 215–234. https://doi.org/10.1039/ a902202c
[9] Banyal, A., Tiwari, S., Sharma, A., Chanana, I., Patel, S. K. S., Kulshrestha, S., & Kumar, P. (2023). Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech, 13(6), 211. https://doi.org/10.1007/ s13205-023-03636-6
[10] Zhou, Meiliang & Hou, Hong-Li & Zhu, Xue-Mei & Shao, Ji-Rong & Sun, Zhan-Min & Tang, Yi-Xiong. (2010). Molecular regulation of the terpenoid indole alkaloids pathway in the Catharanthus roseus medicinal plant. Journal of Medicinal Plants Research December Special Review. 425. 2760-2772.
[11] Sidkey, B. (2022). Effect of plant growth regulators on secondary metabolites accumulation and antioxidant activity of Catharanthus roseus L.. 11. 241-245.
[12] Zhang, J., Hansen, L. G., Gudich, O., Viehrig, K., M. Lassen, L. M., Schrübbers, L., Adhikari, K. B., Rubaszka, P., Carrasquer-Alvarez, E., Chen, L., Lehka, B., Haidar, A. K., Nallapareddy, S., Giannakou, K., Laloux, M., Arsovska, D., K. Jørgensen, M. A., G. Chan, L. J., Kristensen, M., . . . Keasling, J. D. (2022). A microbial supply chain for the production of the anticancer drug vinblastine. Nature, 609(7926), 341-347. https:// doi.org/10.1038/s41586-022-05157-3
[13] Pirosa, M. C., & Peccatori, F. A. (2023). Lymphomas in pregnancy. Hematological oncology, 41 Suppl 1, 70–74. https:// doi.org/10.1002/hon.3150
[14] Martino, E., Casamassima, G., Castiglione, S., Cellupica, E., Pantalone, S., Papagni, F., Rui, M., Siciliano, A. M., & Collina, S. (2018). Vinca alkaloids and analogs as anticancer agents: Looking back, peering ahead. Bioorganic & Medicinal Chemistry Letters, 28(17), 2816-2826. https://doi.org/10.1016/ j.bmcl.2018.06.044
[15] Yasuda, H., Komatsu, N., Ando, J., & Ando, M. (2022). Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations. Clinical lymphoma, myeloma & leukemia, 22(11), 805–811. https://doi.org/10.1016/ j.clml.2022.07.008
[16] On some morbid appearances of the absorbent glands and spleen. Hodgkin Hodgkin. Med Chir Trans. 1832;17:68–114.
[17] Papa, G., Mandelli, F., Anselmo, A. P., De Luca, A. M., Maurizienrici, R., Mauro, F., Testi, A. M., Amadori, S., & Biagini, C. (1982). Treatment of MOPP-resistant Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). European journal of cancer & clinical oncology, 18(9), 803–806. https://doi.org/10.1016/0277-5379(82)90188-2
[18] Schimmoeller, C. J., Bastian, C., Fleming, J., & Morales, J. (2023). A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors. Cureus, 15(7), e41660. https://doi. org/10.7759/cureus.41660
[19] Canellos G. P. (1990). Can MOPP be replaced in the treatment of advanced Hodgkin’s disease? Seminars in oncology, 17(1 Suppl 2), 2–6.
[20] Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., & Rosenberg, S. A. (2002). Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature prospective clinical trial results. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 20(3), 630–637. https://doi.org/10.1200/ JCO.2002.20.3.630
[21] von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Meissner, J., Zijlstra, J. M., Soekler, M., Stein, H., Eich, H. T., Mueller, R. P., Diehl, V., Borchmann, P., & Engert, A. (2012). Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 30(9), 907–913. https:// doi.org/10.1200/JCO.2011.38.5807
[22] Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., Jr, & Miller, T. P. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. The New England journal of medicine, 328(14), 1002–1006. https://doi.org/10.1056/ NEJM199304083281404
[23] Sebastian, J., & Rathinasamy, K. (2023). Microtubules and Cell Division: Potential Pharmacological Targets in Cancer Therapy. Current drug targets, 10.2174/13894501246662307310 Dean&Francis 94837. Advanced online publication. https://doi.org/10.2174/138 9450124666230731094837
[24] Panda, D., Jordan, M. A., Chu, K. C., & Wilson, L. (1996). Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. The Journal of Biological Chemistry, 271(47), 29807–29812. https://doi. org/10.1074/jbc.271.47.29807
[25] Jordan, M. A., Thrower, D., & Wilson, L. (1992). Effects of vinblastine, podophyllotoxin, and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. Journal of cell science, 102 ( Pt 3), 401–416. https://doi. org/10.1242/jcs.102.3.401
[26] Vinblastine: MedlinePlus drug information. (n.d.).
[27] https://medlineplus.gov/druginfo/meds/a682848.html
[29] Cech, N. B., & Oberlies, N. H. (2023). From plant to cancer drug: Lessons learned from the discovery of taxol. Natural Product Reports, 40(7), 1153-1157. https://doi.org/10.1039/ d3np00017f
[31] Mann J. (2002). Natural products in cancer chemotherapy: past, present and future. Nature reviews. Cancer, 2(2), 143–148. https://doi.org/10.1038/nrc723
[32] Guéritte-Voegelein, F., Guénard, D., Lavelle, F., Le Goff, M. T., Mangatal, L., & Potier, P. (1991). Relationships between the structure of taxol analogs and their antimitotic activity. Journal of medicinal chemistry, 34(3), 992–998. https://doi.org/10.1021/ jm00107a017
[33] Zhu, L., & Chen, L. (2019). Progress in research on paclitaxel and tumor immunotherapy. Cellular & Molecular Biology Letters, 24. https://doi.org/10.1186/s11658-019-0164-y
[34] Robert A. Holton, Carmen Somoza, Hyeong Baik Kim, Feng Liang, Ronald J. Biediger, P. Douglas Boatman, Mitsuru Shindo, Chase C. Smith, Soekchan Kim, and
[35] Journal of the American Chemical Society 1994 116 (4), 1597-1598
[36] DOI: 10.1021/ja00083a066
[37] Nicolaou, K. C., Yang, Z., Liu, J. J., Ueno, H., Nantermet, P. G., Guy, R. K., Claiborne, C. F., Renaud, J., Couladouros, E. A., Paulvannan, K., & Sorensen, E. J. (1994). Total synthesis of taxol. Nature, 367(6464), 630-634. https://doi. org/10.1038/367630a0
[38] Kanda, Y., Nakamura, H., Umemiya, S., Puthukanoori, R. K., Murthy Appala, V. R., Gaddamanugu, G. K., Paraselli, B. R., & Baran, P. S. (2020). Two-Phase Synthesis of Taxol. Journal of the American Chemical Society, 142(23), 10526–10533. https:// doi.org/10.1021/jacs.0c03592
[39] Hu, Y. J., Gu, C. C., Wang, X. F., Min, L., & Li, C. C. (2021). Asymmetric Total Synthesis of Taxol. Journal of the American Chemical Society, 143(42), 17862–17870. https://doi. org/10.1021/jacs.1c09637
[40] SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277(5698), 665-667. https://doi.org/10.1038/277665a0
[41] Kingston, David. (2001). Taxol, a Molecule for All Seasons. Chemical Communications - CHEM COMMUN. 10. 867-880. 10.1039/b100070p.
[42] Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D., & Pietenpol, J. A. (1998). Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. The Journal of Biological Chemistry, 273(46), 30777–30784. https://doi.org/10.1074/ jbc.273.46.30777
[43] Guo, R., Li, L., Wang, Y., et al. (2016). A historical account of natural drug chemistry: Steroidal compounds. Chinese Traditional and Herbal Drugs, 47(8), 1251-1264.
[44] Sanford, L.L., Deahl, K.L., Sinden, S.L., & Ladd, T.L. (1992). Glycoalkaloid contents in tubers from Solanum tuberosum populations selected for potato leafhopper resistance. American Potato Journal, 69, 693-703.
[45] Bejarano, L., Mignolet, E., Devaux, A., Espinola, N.Y., Carrasco, E., & Larondelle, Y. (2000). Glycoalkaloids in potato tubers: the effect of variety and drought stress on the α‐solanine and α‐chaconine contents of potatoes. Journal of the Science of Food and Agriculture, 80, 2096-2100.
[46] Zhang, G., (2006). Experimental study on the effects of Guben Yiliao II on human A_(549) lung cancer cells and Lewis lung cancer in mice.
[47] Zhang, Y., Zhang, L., Sun, X., Cao, X., Shang, W., Gong, X., Ma, C., Nan, N., Li, P., Yu, W., Yang, W., & Wang, M. (2017). Gubenyiliu II Inhibits Breast Tumor Growth and Metastasis Associated with Decreased Heparanase Expression and Phosphorylation of ERK and AKT Pathways. Molecules: A Journal of Synthetic Chemistry and Natural Product Chemistry, 22(5). https://doi.org/10.3390/molecules22050787
[48] Bai, Y., Cui, X., Wang, B., Wang, Y., Yang, L., Liu, J., & Qin, J. (2021). Mechanism study of Guben Yiliao II inhibiting the occurrence of laryngeal cancer in Hep-2 tumor-bearing mice. Journal of PLA Medical School, (09), 11-16.
[49] Liu, J., Qian, H., Xu, Z., Zhang, L., Ye, P., Tian, A., & Yang, H. (2014). Antitumor effect of Guben Yiliao III combined with gemcitabine on xenograft tumors of human pancreatic cancer in nude mice. Chinese Journal of Experimental Animals, (03), 98- 102.
[50] Li, Q. W., Zhang, G. L., Hao, C. X., Ma, Y. F., Sun, X., Zhang, Y., Cao, K. X., Li, B. X., Yang, G. W., & Wang, X. M. (2021). SANT, a novel Chinese herbal monomer combination, decreases tumor growth and angiogenesis via modulating autophagy in heparanase-overexpressed triple-negative breast cancer. Journal of Ethnopharmacology, 266, 113430. https://doi. org/10.1016/j.jep.2020.113430
[51] Putri Gono, C. M., Ahmadi, P., Hertiani, T., Septiana, E., Putra, M. Y., & Chianese, G. (2022). A Comprehensive Update on the Bioactive Compounds from Seagrasses. Marine Drugs, Dean&Francis 20(7). https://doi.org/10.3390/md20070406
[52] Dawes, C.J. (1998). Google books. Marine Botany, 2nd Edition. https://books.google.com.hk/books?id=IHGIL7az7p0C &pg=PA1&source=gbs_toc_r&cad=3#v=onepage&q&f=false
[53] Lu, W. Y., Li, H. J., Li, Q. Y., & Wu, Y. C. (2021). Application of marine natural products in drug research. Bioorganic & medicinal chemistry, 35, 116058. https:// doi.org/10.1016/j.bmc.2021.116058
[54] Karthikeyan, A., Joseph, A., & Nair, B. G. (2022). Promising bioactive compounds from the marine environment and their potential effects on various diseases. Journal of Genetic Engineering and Biotechnology, 20(1), 1-38. https://doi. org/10.1186/s43141-021-00290-4
[55] Murphy, C., Hotchkiss, S., Worthington, J. et al. The potential of seaweed as a source of drugs for use in cancer chemotherapy. J Appl Phycol 26, 2211–2264 (2014). https://doi. org/10.1007/s10811-014-0245-2
[56] Wang, Z., Xu, Z., Yang, X., Li, M., Yip, R. C. S., Li, Y., & Chen, H. (2023). Current application and modification strategy of marine polysaccharides in tissue regeneration: A review. Biomaterials advances, 154, 213580. Advanced online publication. https://doi.org/10.1016/j.bioadv.2023.213580
[57] Santos, G. (1989). Carrageenans of species of Eucheuma J. Agardh and Kappaphycus Doty (Solieriaceae, Rhodophyta). Aquatic Botany, 36(1), 55-67. https://doi.org/10.1016/0304- 3770(89)90091-0
[58] Qureshi, D., Nayak, S. K., Maji, S., Kim, D., Banerjee, I., & Pal, K. (2019). Carrageenan: A Wonder Polymer from Marine Algae for Potential Drug Delivery Applications. Current pharmaceutical design, 25(11), 1172–1186. https://doi.org/10.21 74/1381612825666190425190754
[59] Cunha, L., & Grenha, A. (2016). Sulfated Seaweed Polysaccharides as Multifunctional Materials in Drug Delivery Applications. Marine drugs, 14(3), 42. https://doi.org/10.3390/ md14030042
[60] Buck, C. B., Thompson, C. D., Roberts, J. N., Müller, M., Lowy, D. R., & Schiller, J. T. (2006). Carrageenan is a potent inhibitor of papillomavirus infection. PLoS pathogens, 2(7), e69. https://doi.org/10.1371/journal.ppat.0020069
[61] Liu, Z., Gao, T., Yang, Y., Meng, F., Zhan, F., Jiang, Q., & Sun, X. (2019). Anticancer Activity of Porphyran and Carrageenan from Red Seaweeds. Molecules (Basel, Switzerland), 24(23), 4286. https://doi.org/10.3390/ molecules24234286
[62] Luo, M., Shao, B., Nie, W., Wei, X. W., Li, Y. L., Wang, B. L., He, Z. Y., Liang, X., Ye, T. H., & Wei, Y. Q. (2015). Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy. Scientific reports, 5, 11062. https://doi.org/10.1038/srep11062
[63] Ehrke, M. (2003). Immunomodulation in cancer therapeutics. International Immunopharmacology, 3(8), 1105- 1119. https://doi.org/10.1016/S1567-5769(03)00021-3
[64] Raman, M., Devi, V., & Doble, M. (2015). Biocompatible ι-carrageenan-γ-maghemite nanocomposite for biomedical applications – synthesis, characterization, and in vitro anticancer efficacy. Journal of Nanobiotechnology, 13. https://doi. org/10.1186/s12951-015-0079-3
[65] Jin, W., Yu, Y., Hou, W., Wang, G., Zhu, Z., He, J., Cheng, S., & Huang, Q. (2019). Molecular characteristics of kappa-selenocarrageenan and application in green synthesis of silver nanoparticles. International journal of biological macromolecules, 141, 529–537. https://doi.org/10.1016/ j.ijbiomac.2019.09.016
[66] Ling, Na. (2011). Growth Inhibition and Cell Cycle Arrest of Kappa-Selenocarrageenan and Paclitaxel on HepG2 Cells. Advanced Materials Research. 343-344. 530-534. 10.4028/www. scientific.net/AMR.343-344.530.
[67] Prasedya, E. S., Miyake, M., Kobayashi, D., & Hazama, A. (2016). As demonstrated by FUCCI imaging, Carrageenan delays cell cycle progression in human cancer cells in vitro. BMC Complementary and Alternative Medicine, 16. https://doi. org/10.1186/s12906-016-1199-5
[68] Shang, Q., Sun, W., Shan, X., Jiang, H., Cai, C., Hao, J., Li, G., & Yu, G. (2017). Carrageenan-induced colitis is associated with the decreased population of anti-inflammatory bacterium Akkermansia muciniphila in the gut microbiota of C57BL/6J mice. Toxicology letters, 279, 87–95. https://doi.org/10.1016/ j.toxlet.2017.07.904
[69] Berteau, O., & Mulloy, B. (2003). Sulfated fucans, fresh perspectives: Structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology, 13(6), 29R-40R. https:// doi.org/10.1093/glycob/cwg058
[70] Jin, J. O., Yadav, D., Madhwani, K., Puranik, N., Chavda, V., & Song, M. (2022). Seaweeds in the Oncology Arena: Anticancer Potential of Fucoidan as a Drug-A Review. Molecules (Basel, Switzerland), 27(18), 6032. https://doi. org/10.3390/molecules27186032
[71] Lin, Y., Qi, X., Liu, H. et al. The anticancer effects of fucoidan: a review of both in vivo and in vitro investigations. Cancer Cell Int 20, 154 (2020). https://doi.org/10.1186/s12935- 020-01233-8
[72] Park, H. Y., Park, H., Jeong, W., Yoon, D., Han, M. H., Lee, S., Choi, G., Yim, J., Lee, J. M., Kim, H., Kim, Y., Choi, W., Kim, S., Kim, S., Cha, J., & Choi, Y. H. (2017). Induction of p53-Independent Apoptosis and G1 Cell Cycle Arrest by Fucoidan in HCT116 Human Colorectal Carcinoma Cells. Marine Drugs, 15(6). https://doi.org/10.3390/md15060154
[73] Li, J., Chen, K., Li, S., Liu, T., Wang, F., Xia, Y., Lu, J., Zhou, Y., & Guo, C. (2016). Pretreatment with Fucoidan from Fucus vesiculosus Protected against ConA-Induced Acute Liver Injury by Inhibiting Intrinsic and Extrinsic Apoptosis. PloS one, 11(4), e0152570. https://doi.org/10.1371/journal. pone.0152570 Dean&Francis
[74] Teruya, T., Tatemoto, H., Konishi, T., & Tako, M. (2009). Structural characteristics and in vitro macrophage activation of acetyl fucoidan from Cladosiphon okamuranus. Glycoconjugate journal, 26(8), 1019–1028. https://doi.org/10.1007/s10719-008- 9221-x
[75] Zahariev, N., Katsarov, P., Lukova, P., & Pilicheva, B. (2023). Novel Fucoidan Pharmaceutical Formulations and Their Potential Application in Oncology—A Review. Polymers, 15(15). https://doi.org/10.3390/polym15153242
[76] Kaur, M., Saini, K.C., Ojah, H. et al. Abiotic stress in algae: response, signaling and transgenic approaches. J Appl Phycol 34, 1843–1869 (2022). https://doi.org/10.1007/s10811- 022-02746-7
[77] Marine Conservation Institute. The Marine Protection Atlas. https://mpatlas.org (2023)
[78] Külköylüoğlu, O., Çelikbaş, B., & Ataman, A. (2022). Habitat destruction in wetlands affects the occurrence patterns of Ostracoda (Crustacea) species amid different aquatic habitats. Aquatic ecology, 56(3), 605–618. https://doi.org/10.1007/ s10452-021-09934-6
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
